Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bipinchandra Patel

Vascular Surgery Livonia, MI Doctor of Osteopathy

NPI 1871706770 CMS profile 85279

15370 Levan Road, Suite 1, Livonia, MI 48154

Open in the dashboard

General payments

$23,061

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bipinchandra Patel of Livonia, MI is reported in the CMS Open Payments database as having received $23,061 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,269 56
2024 General $2,434 34
2023 General $8,013 66
2022 General $3,527 50
2021 General $1,005 36
2020 General $414 19
2019 General $399 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bipinchandra Patel
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Bipinchandra Patel were reported at $7,269. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Bipinchandra Patel Vascular Surgery median Middle half National median
2019 $399 $796 $226–$2,363 $163
2020 $414 $348 $118–$1,110 $114
2021 $1,005 $471 $158–$1,421 $132
2022 $3,527 $725 $222–$2,183 $149
2023 $8,013 $836 $257–$2,440 $160
2024 $2,434 $909 $252–$2,619 $164
2025 $7,269 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $10,096 85 payments
  2. Endologix, Inc. $4,263 20 payments
  3. W. L. Gore & Associates, Inc. $2,423 19 payments
  4. Silk Road Medical, Inc. $1,647 5 payments
  5. Boston Scientific Corporation $983 39 payments
  6. Bard Peripheral Vascular, Inc. $694 9 payments
  7. Janssen Pharmaceuticals, Inc $346 21 payments
  8. Kerecis Limited $317 3 payments
  9. LeMaitre Vascular, Inc. $310 4 payments
  10. Pfizer Inc. $208 13 payments
  11. Other $1,774 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,819 265 payments
  2. Travel and Lodging $8,242 21 payments
Products named General payments · program years 2019–2025
  1. Alto Abdominal Stent Graft System $2,971 12 payments
  2. PERCLOSE PROGLIDE $2,302 12 payments
  3. ACCULINK $2,082 5 payments
  4. OMNILINK ELITE $1,984 15 payments
  5. ENROUTE Transcarotid Stent $1,647 5 payments
  6. ENROUTE Transcarotid Neuroprotection System $1,647 5 payments
  7. SUPERA $1,381 11 payments
  8. ENDOCROSS Device $977 7 payments
  9. Torus Stent Graft System $977 7 payments
  10. GORE TAG Conformable Thoracic Endoprosthesis $634 3 payments
  11. Other $11,000 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

317

Median for General Surgery: 59

Drug cost

$52,027

Median for General Surgery: $393

Branded share of claims

58.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 28 $31,187
Xarelto Rivaroxaban Brand 20 $17,593
Clopidogrel Clopidogrel Bisulfate Brand 81 $1,237
Gabapentin Generic 64 $657
Pentoxifylline Generic 21 $612
Cilostazol Generic 35 $569
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $157
Prednisone Generic 12 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$296,297

Of which drugs: $328

Medicare patients

1,271

Average age 75

Services billed

5,379

721 women, 550 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 53%
Chronic kidney disease 53%
Diabetes 51%
Heart failure 46%
COPD 35%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 41 3,150 $328

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DEFINITY
  • Lantheus Medical Imaging, Inc. $31
$31 — —
ELIQUIS
  • PFIZER INC. $8
$8 28 —
PAXLOVID
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record